Which gut test answers your question?

Gut health tests cover very different jobs. A microbial profile, a cancer screen and a test for intestinal inflammation can all use stool, but they do not answer the same question. The biggest panel is not always the most useful one.

If symptoms keep coming back, I would start with the history: when they began, what makes them worse, medicines, travel, bowel habits and other health problems. That helps us choose the next test. A stool sample cannot show every part of the gut; sometimes blood tests, breath tests, a procedure or a test of gut movement make more sense.

The method matters more than the size of the report. Two companies can use stool and return pages of advice while measuring different things.

Shotgun DNA sequencing reads DNA across many microbes and genes. It can describe organisms and their possible functions. Targeted 16S rRNA-gene sequencing reads a bacterial DNA marker; despite the name, it does not measure RNA activity. GutID reads a longer 16S–ITS–23S region, which is still different from surveying all microbial genes.

RNA sequencing measures gene expression in the collected sample. Stool chemistry measures substances such as short-chain fatty acids, fat or bile acids. Immune-marker assays can measure calprotectin or lactoferrin. A gene, its expression and the chemical product are three different measurements.

PCR checks a chosen list of genetic targets. A targeted pathogen result can be useful in the right setting, but detecting DNA does not always mean a live organism caused the symptoms. Culture and microscopy ask different questions again.

I practice precision medicine, and I like these tests for people interested in probiotics or other gut interventions. We need good data and ongoing measurement. That means asking both whether the measurement is reliable and whether it helps us make a useful change.

An international consensus statement finds too little evidence for widespread routine clinical microbiome testing. It also questions broad dysbiosis scores and strict healthy ranges for individual species. A flagged bacterium or a lower diversity score is not a diagnosis on its own.

In a 2026 NIST study, seven consumer services tested portions of the same homogenized single-donor stool sample. The reports differed, and repeatability within a service varied. The companies were anonymous, so the study cannot tell us how Jona compares with Tiny Health.

Tiny Health has a small randomized study in infants born by C-section. Babies in a program combining reports, education, coaching, diet advice and probiotic recommendations had less parent-reported eczema. The study had company ties, families knew their group, and eczema was an additional outcome. It does not separate the test’s value from the full program or establish adult benefit.

Company pages can tell us what a product measures and how it generates advice. They do not establish that one company is best. Clinical markers in a combined panel may have a clear role even when other scores or suggested interventions have less evidence.

The comparison below covers 39 named products, panel variants and clinical test categories. It is not a list of every lab order or regional offer. Search by a test, method, symptom or marker, or choose a category.

Who it may suit describes a possible use, not proof that buying the test improves health. Check the exact sample report, collection rules, access and total cost, including interpretation and follow-up. Menus and availability can change.

Choose the outcome first: less pain or bloating, fewer urgent stools, easier bowel movements or another clear goal. Record a baseline. Pick one or two changes the person can carry out. Food advice needs to fit their meals, budget and cooking habits. I don’t even cook, so an impressive list of foods is not much help unless I can work it into how I already eat.

For a probiotic, check evidence for the strain or combination, dose and condition. The AGA explains why these details matter. A low abundance in a stool report does not itself tell us which probiotic will help.

Track symptoms and bowel habits alongside the lab result. When relevant, follow a clinical marker with a clear purpose, such as calprotectin during IBD care. A changed microbial profile shows a change in that measurement; it does not by itself prove the intervention caused a health gain.

There is no one schedule for every gut test. Set the interval to the question, the intervention and the result that would change care. H. pylori may need a test of cure; C. difficile should not get a routine test of cure after symptoms resolve.

If you repeat a microbiome test, use the same lab and method where possible. Ask whether the lab changed its analysis or reference data. Biomesight’s 2026 pipeline update changed reported numbers without a new sample, and the company reprocessed its own past samples for comparison.

Note diet, medicines, antibiotics, illness, sample timing and collection instructions when judging a change. Don’t stop a prescribed medicine just to get a cleaner comparison without discussing it with your clinician.

Before ordering, ask what you would do with each possible result. If the answer would leave the plan unchanged, another test may add cost without helping the next decision.